Characteristics of 5-year survivors of childhood Hodgkin lymphoma in the CCSS
| . | HL cohort, n (%)* . | Male, n (%)* . | Female, n (%) . | P† . |
|---|---|---|---|---|
| All eligible CCSS survivors‡ | 2633 | 1507 (57) | 1126 (43) | |
| Treatment era | .63 | |||
| 1970-1979 | 1546 (59) | 879 (58) | 667 (59) | |
| 1980-1986 | 1087 (41) | 628 (42) | 459 (41) | |
| Age at diagnosis | < .001 | |||
| 0-9 y | 476 (18) | 379 (25) | 100 (90) | |
| 10-14 y | 884 (34) | 490 (33) | 394 (35) | |
| 15-21 y | 1273 (48) | 641 (43) | 632 (56) | |
| Participants, n§ | 1927 | 1049 | 878 | |
| Treatment era | .30 | |||
| 1970-1979 | 1097 (57) | 586 (56) | 511 (58) | |
| 1980-1986 | 830 (43) | 463 (44) | 367 (42) | |
| Age at diagnosis | < .001 | |||
| 0-9 y | 329 (17) | 244 (23) | 85 (10) | |
| 10-14 y | 663 (34) | 350 (33) | 313 (36) | |
| 15-21 y | 935 (49) | 455 (43) | 480 (55) | |
| Race/ethnicity‖ | .20 | |||
| White, non-Hispanic | 1653 (86) | 892 (85) | 761 (87) | |
| Other | 268 (14) | 156 (15) | 112 (13) | |
| Missing, n | 6 | 1 | 5 | |
| Household income‖ | .12 | |||
| $0-19 999 | 288 (17) | 167 (18) | 121 (15) | |
| ≥ $20 000 | 1423 (83) | 753 (82) | 670 (85) | |
| Missing, n | 216 | 129 | 87 | |
| Education‖ | < .001 | |||
| Through high school | 503 (27) | 323 (32) | 180 (22) | |
| After High School | 1339 (73) | 691 (68) | 648 (78) | |
| Missing, n | 85 | 35 | 50 | |
| Treatment group¶ | .77 | |||
| Radiation only | 548 (33) | 285 (32) | 263 (33) | |
| Chemotherapy + radiation | 1024 (61) | 552 (62) | 472 (60) | |
| Chemotherapy only | 98 (6) | 52 (6) | 46 (6) | |
| Missing | 257 | 160 | 97 | |
| Splenectomy (yes) | 1441 (76) | 760 (74) | 681 (79) | .02 |
| Chemotherapy categories# | .10 | |||
| Radiation only | 548 (33) | 285 (32) | 263 (34) | |
| Chemotherapy, no anthracycline | 689 (41) | 355 (40) | 334 (43) | |
| Chemotherapy, including anthracycline | 428 (26) | 247 (28) | 181 (23) | |
| Missing | 262 | 162 | 100 | |
| Anthracycline score# | .21 | |||
| 0 | 1237 (76) | 640 (74) | 597 (78) | |
| 1 | 174 (11) | 98 (11) | 79 (10) | |
| 2 | 166 (10) | 99 (12) | 67 (9) | |
| 3 | 47 (3) | 25 (3) | 22 (3) | |
| Missing, n | 303 | 187 | 116 | |
| Alkylating agents score# | .02 | |||
| 0 | 606 (44) | 317 (43) | 289 (44) | |
| 1 | 118 (9) | 58 (8) | 60 (9) | |
| 2 | 108 (8) | 45 (6) | 63 (10) | |
| 3 | 555 (40) | 316 (43) | 239 (37) | |
| Missing, n | 540 | 313 | 227 | |
| RT field by dose | < .01 | |||
| Chemotherapy only | 98 (6) | 52 (6) | 46 (6) | |
| Supradiaphragmatic, < 30 Gy** | 156 (10) | 104 (12) | 52 (7) | |
| Supradiaphragmatic, ≥ 30 Gy** | 406 (25) | 201 (24) | 205 (27) | |
| Infradiaphragmatic + supradiaphragmatic, < 30 Gy**†† | 147 (9) | 82 (10) | 65 (9) | |
| Infradiaphragmatic + supradiaphragmatic, ≥ 30 Gy**†† | 790 (49) | 409 (48) | 381 (51) | |
| Missing, n | 330 | 201 | 129 |
| . | HL cohort, n (%)* . | Male, n (%)* . | Female, n (%) . | P† . |
|---|---|---|---|---|
| All eligible CCSS survivors‡ | 2633 | 1507 (57) | 1126 (43) | |
| Treatment era | .63 | |||
| 1970-1979 | 1546 (59) | 879 (58) | 667 (59) | |
| 1980-1986 | 1087 (41) | 628 (42) | 459 (41) | |
| Age at diagnosis | < .001 | |||
| 0-9 y | 476 (18) | 379 (25) | 100 (90) | |
| 10-14 y | 884 (34) | 490 (33) | 394 (35) | |
| 15-21 y | 1273 (48) | 641 (43) | 632 (56) | |
| Participants, n§ | 1927 | 1049 | 878 | |
| Treatment era | .30 | |||
| 1970-1979 | 1097 (57) | 586 (56) | 511 (58) | |
| 1980-1986 | 830 (43) | 463 (44) | 367 (42) | |
| Age at diagnosis | < .001 | |||
| 0-9 y | 329 (17) | 244 (23) | 85 (10) | |
| 10-14 y | 663 (34) | 350 (33) | 313 (36) | |
| 15-21 y | 935 (49) | 455 (43) | 480 (55) | |
| Race/ethnicity‖ | .20 | |||
| White, non-Hispanic | 1653 (86) | 892 (85) | 761 (87) | |
| Other | 268 (14) | 156 (15) | 112 (13) | |
| Missing, n | 6 | 1 | 5 | |
| Household income‖ | .12 | |||
| $0-19 999 | 288 (17) | 167 (18) | 121 (15) | |
| ≥ $20 000 | 1423 (83) | 753 (82) | 670 (85) | |
| Missing, n | 216 | 129 | 87 | |
| Education‖ | < .001 | |||
| Through high school | 503 (27) | 323 (32) | 180 (22) | |
| After High School | 1339 (73) | 691 (68) | 648 (78) | |
| Missing, n | 85 | 35 | 50 | |
| Treatment group¶ | .77 | |||
| Radiation only | 548 (33) | 285 (32) | 263 (33) | |
| Chemotherapy + radiation | 1024 (61) | 552 (62) | 472 (60) | |
| Chemotherapy only | 98 (6) | 52 (6) | 46 (6) | |
| Missing | 257 | 160 | 97 | |
| Splenectomy (yes) | 1441 (76) | 760 (74) | 681 (79) | .02 |
| Chemotherapy categories# | .10 | |||
| Radiation only | 548 (33) | 285 (32) | 263 (34) | |
| Chemotherapy, no anthracycline | 689 (41) | 355 (40) | 334 (43) | |
| Chemotherapy, including anthracycline | 428 (26) | 247 (28) | 181 (23) | |
| Missing | 262 | 162 | 100 | |
| Anthracycline score# | .21 | |||
| 0 | 1237 (76) | 640 (74) | 597 (78) | |
| 1 | 174 (11) | 98 (11) | 79 (10) | |
| 2 | 166 (10) | 99 (12) | 67 (9) | |
| 3 | 47 (3) | 25 (3) | 22 (3) | |
| Missing, n | 303 | 187 | 116 | |
| Alkylating agents score# | .02 | |||
| 0 | 606 (44) | 317 (43) | 289 (44) | |
| 1 | 118 (9) | 58 (8) | 60 (9) | |
| 2 | 108 (8) | 45 (6) | 63 (10) | |
| 3 | 555 (40) | 316 (43) | 239 (37) | |
| Missing, n | 540 | 313 | 227 | |
| RT field by dose | < .01 | |||
| Chemotherapy only | 98 (6) | 52 (6) | 46 (6) | |
| Supradiaphragmatic, < 30 Gy** | 156 (10) | 104 (12) | 52 (7) | |
| Supradiaphragmatic, ≥ 30 Gy** | 406 (25) | 201 (24) | 205 (27) | |
| Infradiaphragmatic + supradiaphragmatic, < 30 Gy**†† | 147 (9) | 82 (10) | 65 (9) | |
| Infradiaphragmatic + supradiaphragmatic, ≥ 30 Gy**†† | 790 (49) | 409 (48) | 381 (51) | |
| Missing, n | 330 | 201 | 129 |
Percentages are calculated on the basis of the number of values not missing for each factor as the denominator.
Comparisons are based on 2-tail chi-square for categorical variables.
All US survivors with HL who met eligibility criteria for CCSS study and were included in national death index search (Figure 1).
HL survivors who participated in the study (at baseline).
Race, income, and education were not reported at baseline by some participants.
Summary data on treatment data for first diagnosis of HL available in 1675 respondents. Other specific treatment factors have various numbers of missing values as indicated.
Chemotherapy categories are mutually exclusive. Exposure to anthracycline and alkylating agents was expressed as a total score on the basis of the tertiles of various alkylating agents received, according to methods reported previously. A score of 0 indicates no exposure to the agent.34
Multiply by 100 to convert gray to rad.
Includes 49 subjects with field limited to infradiaphragmatic sites only.